Abstract:Luminal B breast tumors are notoriously known as high grade breast cancer prone to Tamoxifen resistance and early recurrence. Chromosomal abnormalities are a crucial class of drug targets in cancer which can be classified into numerical and structural rearrangements. Gene amplification is the result of numerical rearrangement that generates multiple copies of an otherwise normal human gene, such as Her2 amplification observed in breast cancer. Gene fusion is the result of structural rearrangement that fuses together pieces of two different genes, such as BCR-ABL gene fusion identified in leukemia. Due to their critical role in causing human cancers and their presence exclusively in the tumor tissues, gene amplifications and fusions provide highly specific drug targets with only minimal side effects. In order to identify these chromosome aberrations that can serve as new therapeutic targets in breast cancer, we developed a novel bioinformatics analysis called “copy number signature analysis”. This is based on the observation that driving gene fusions and their original (wild-type) genes are often amplified in fusion-positive tumors, or tumors without the fusions respectively. This suggests that gene fusions and amplifications may synergize to activate important oncogenes; if directly druggable, these aberrations will provide substantial opportunities for new therapies. Applying this analysis to the newly emerged genomic data from the Cancer Genome Atlas (TCGA) project nominated Nemo-like kinase ( NLK ) as a lead therapeutic target for invasive breast cancer. NLK encodes a serine-threonine mitogen activated protein kinase that plays a pivotal role in transforming growth factor beta pathway and embryo development. Genomic amplifications and rearrangements at NLK locus happen in 7%–9% of breast tumors, which may lead to deregulated serine-threonine kinase activity. Of note, these aberrations preferentially present in luminal B or Her2 positive breast tumors, suggesting their association with these high grade tumors. Most interestingly, transient inhibition of NLK through small RNA interference in multiple breast cancer cell lines harboring NLK deregulations, we observed potent inhibition of cell growth and capability of forming tumor-like colonies, as well as increased sensitivity to Tamoxifen treatment. These data suggest that NLK might be deregulated by genetic events which may promote growth-factor signaling and Tamoxifen resistant phenotype. Molecular assays detecting NLK chromosomal aberrations may serve as a predictive biomarker for endocrine resistance in breast cancer as well as selection of patients for appropriate treatment. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-04-25.

Nemo-Like Kinase Associated With Proliferation And Apoptosis By C-Myb Degradation In Breast Cancer

Pan-cancer analysis of nemo-like kinase (NLK) expression convergence to pancreatic adenocarcinoma that has diagnostic, prognostic and treatment value

Down-regulation of Nicotinamide N-methyltransferase Induces Apoptosis in Human Breast Cancer Cells Via the Mitochondria-Mediated Pathway.

Numb Negatively Regulates the Epithelial-to-mesenchymal Transition in Colorectal Cancer Through the Wnt Signaling Pathway.

Genomic Deregulation And Therapeutic Role Of Nemo-Like Kinase In Luminal B Breast Cancer

LncRNA MBNL1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer

MicroRNA-665 Regulated Cell Proliferation, Migration and Apoptosis by Targeting Nemo-like Kinase in Non-small Cell Lung Cancer

Novel post-transcriptional and post-translational regulation of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1 determine the fate of breast cancer cells to survive or die

Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival

Dysfunction of Ubiquitin Protein Ligase MYCBP2 Leads to Cell Resilience in Human Breast Cancers

MYB mediates downregulation of the colorectal cancer metastasis suppressor heterogeneous nuclear ribonucleoprotein L‐like during epithelial‐mesenchymal transition

Wnt modulates MCL1 to control cell survival in triple negative breast cancer

Comprehensive pan-cancer analysis of expression profiles and prognostic significance for NUMB and NUMBL in human tumors

Dead-Box Rna Helicase Dp103 As A Novel Regulator Of Wnt/Beta-Catenin Signaling Pathway And Promotes Cancer Stem Cell-Like Behavior In Triple Negative Breast Cancers

MELK is an Oncogenic Kinase Essential for Mitotic Progression in Basal-Like Breast Cancer Cells

C-Myb Enhances Breast Cancer Invasion and Metastasis Through the Wnt/β-Catenin/Axin2 Pathway.

Mitotic kinesin-like protein 1, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/β-catenin pathway

C-Myb Enhances Breast Cancer Invasion And Metastasis Through The Wnt/Beta-Catenin/Axin2 Pathway

Circular forms of dedicator of cytokinesis 1 promotes breast cancer progression by derepressing never in mitosis related kinase 2 via sponging miR‐128‐3p

miRNA-200c-3p deficiency promotes epithelial-mesenchymal transition in triple-negative breast cancer by activating CRKL expression